BROWSER UPDATE To gain access to the full experience, please upgrade your browser:
Note: If you are running Internet Explorer 10 and above, make sure it is not in compatibility mode
<![endif]-->New FDA commissioner Scott Gottlieb is reshaping the drug industry with an ambitious agenda. Investors should watch him closely.
A sloppy jobs report had a clear message about wage gains and it isn’t positive news for stock investors.
While General Motors is retreating to its lucrative but shrinking home market, Renault is pinning extravagant hopes on emerging-markets growth.
The market seems to be undervaluing the Japanese tech conglomerate’s collection of stakes in tech companies.
The second season of the streaming service’s “Stranger Things” launches later this month—conveniently about a week after many of the company’s U.S. subscribers will be notified that their prices are going up.
European regulators are turning up the heat on bad loans and Italy’s banks will feel it most.
A key European junk-bond index yields less than 10-year U.S. Treasurys, the global benchmark for risk. It’s worth looking a little closer at this apparent through-the-looking-glass moment.
Expanding product lineup helps the web giant get services into more hands.
The way the stock market reacts to Friday’s jobs report may say more about the stock market than it does about jobs.
A surprise move from the Food and Drug Administration means that a recovery for Teva Pharmaceutical Industries just got much more difficult.
Car stocks have been strong not because of hopes that sales growth can be maintained, but on optimism about the capacity of manufacturers to withstand—even benefit from—the disruptive forces of technology.
Fidelity International, the overseas sister company of U.S.-based Fidelity Investments, said it will soon begin offering equity funds that charge a slightly higher fee when they outperform their benchmark, but less if they underperform.
Testing 10-year highs, Hong Kong’s benchmark Hang Seng looks cheap beside bubbly U.S. indexes—but it’s no bargain unless you really like Chinese banks and one particular tech company.